• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    4/19/23 1:30:55 PM ET
    $ALLR
    $BIOL
    $BLCM
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • VYNE Therapeutics (NASDAQ:VYNE) stock moved upwards by 38.0% to $4.32 during Wednesday's regular session. VYNE Therapeutics's stock is trading at a volume of 36.2 million shares as of 13:30 EST. This is 174722.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $14.1 million.
    • Biolase (NASDAQ:BIOL) shares increased by 36.88% to $0.36. As of 13:30 EST, Biolase's stock is trading at a volume of 21.4 million, which is 4206.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.4 million.
    • Matinas BioPharma Hldgs (AMEX:MTNB) shares rose 26.67% to $0.64. As of 13:30 EST, this security is trading at a volume of 2.1 million shares, making up 774.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $138.9 million.
    • Vallon Pharmaceuticals (NASDAQ:VLON) shares rose 20.02% to $0.51. Vallon Pharmaceuticals's stock is trading at a volume of 2.2 million shares as of 13:30 EST. This is 33.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.8 million.
    • Legend Biotech (NASDAQ:LEGN) stock moved upwards by 18.83% to $62.08. Legend Biotech's stock is trading at a volume of 6.4 million shares as of 13:30 EST. This is 1057.8% of its average full-day volume over the last 100 days. The company's market cap stands at $10.2 billion.
    • iBio (AMEX:IBIO) shares rose 16.66% to $1.26. The current volume of 539.3K shares is 16.3% of iBio's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $15.5 million.

    Losers

    • Allarity Therapeutics (NASDAQ:ALLR) shares decreased by 42.2% to $0.67 during Wednesday's regular session. The current volume of 13.9 million shares is 788.1% of Allarity Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST).
    • Femasys (NASDAQ:FEMY) stock fell 19.05% to $1.02. The current volume of 263.6K shares is 738.6% of Femasys's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $12.1 million.
    • Celyad Oncology (NASDAQ:CYAD) stock decreased by 19.01% to $0.65. The market value of their outstanding shares is at $14.6 million.
    • Citius Pharma (NASDAQ:CTXR) stock decreased by 17.88% to $1.35. Trading volume for this security as of 13:30 EST is 3.1 million, which is 339.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $198.1 million.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) stock declined by 14.95% to $3.13. HTG Molecular Diagnostics's stock is trading at a volume of 244.1K shares as of 13:30 EST. This is 77.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.2 million.
    • Bellicum Pharmaceuticals (NASDAQ:BLCM) stock decreased by 14.75% to $0.44. Bellicum Pharmaceuticals's stock is trading at a volume of 2.1 million shares as of 13:30 EST. This is 223.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $BIOL
    $BLCM
    $CTXR

    CompanyDatePrice TargetRatingAnalyst
    Legend Biotech Corporation
    $LEGN
    2/12/2026$24.00Buy → Neutral
    Rothschild & Co Redburn
    Legend Biotech Corporation
    $LEGN
    1/22/2026$21.00Buy → Hold
    TD Cowen
    Legend Biotech Corporation
    $LEGN
    1/7/2026$75.00Outperform
    Oppenheimer
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    iBio Inc.
    $IBIO
    10/21/2025$5.00Outperform
    Oppenheimer
    iBio Inc.
    $IBIO
    10/17/2025$2.00Outperform
    Leerink Partners
    Legend Biotech Corporation
    $LEGN
    10/7/2025$40.00Overweight
    Cantor Fitzgerald
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    More analyst ratings

    $ALLR
    $BIOL
    $BLCM
    $CTXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    3/27/26 5:00:26 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Elefant Dov

    4 - FEMASYS INC (0001339005) (Issuer)

    3/27/26 5:00:26 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Larsen Charles

    4 - FEMASYS INC (0001339005) (Issuer)

    3/27/26 5:00:25 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ALLR
    $BIOL
    $BLCM
    $CTXR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

    Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings availableCRANFORD, N.J., March 24, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that members of its commercial and medical affairs teams will attend the USCLC Annual Workshop 2026. The meeting, titled "Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics, and Future Directions," will take place on March 26, 2026, at the Hyatt Regency Denver at Colorado Convention

    3/24/26 8:00:00 AM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo

    3/16/26 4:30:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIOL
    $BLCM
    $CTXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ALLR
    $BIOL
    $BLCM
    $CTXR
    SEC Filings

    View All

    $ALLR
    $BIOL
    $BLCM
    $CTXR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Legend Biotech downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Legend Biotech from Buy to Neutral and set a new price target of $24.00

    2/12/26 7:23:25 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech downgraded by TD Cowen with a new price target

    TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00

    1/22/26 8:26:15 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Legend Biotech with a new price target

    Oppenheimer initiated coverage of Legend Biotech with a rating of Outperform and set a new price target of $75.00

    1/7/26 8:37:12 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Femasys Inc.

    PRE 14A - FEMASYS INC (0001339005) (Filer)

    3/27/26 4:46:25 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Legend Biotech Corporation

    144 - Legend Biotech Corp (0001801198) (Subject)

    3/26/26 4:27:01 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - FEMASYS INC (0001339005) (Filer)

    3/20/26 5:16:38 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Director Lepore Patrick G bought $43,800 worth of shares (15,000 units at $2.92), increasing direct ownership by 41% to 51,472 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    1/16/25 6:06:19 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:37 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:02 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIOL
    $BLCM
    $CTXR
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

    --Existing investors, including Femasys' largest shareholders, reaffirm confidence in Femasys' strategy for growth and impact in women's health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today the closing of $8 million in financing. This funding will provide critical resources to accelerate commercialization efforts and strengthen the company's ability to address significant unmet needs in women's reproductive health. To underscore this momentum, Femasys' largest shareholder, Jorey Chernett also provided co

    9/2/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Legend Biotech Appoints Carlos Santos as Chief Financial Officer

    SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025. Mr. Santos is a seasoned finance executive who has led financial operations in the pharmaceutical and technology sectors across the United States, Latin America, Europe, the Middle East, and Africa. At Legend, he will oversee financial operations to work to ensure a robust balance sheet and achieve and maintain profitability. "On behalf

    8/18/25 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIOL
    $BLCM
    $CTXR
    Financials

    Live finance-specific insights

    View All

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo

    3/16/26 4:30:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

    CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients treated with CARVYKTI®CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settingsAdvanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN)

    3/10/26 7:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

    SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presen

    2/24/26 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIOL
    $BLCM
    $CTXR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

    SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    11/27/24 4:05:31 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by iBio Inc.

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    11/14/24 4:48:52 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care